Dimer

Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy

Retrieved on: 
Tuesday, December 6, 2022

IRVING, Texas and SINGAPORE, Dec. 6, 2022 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced a strategic collaboration to advance clinical development of Hummingbird Bioscience's anti-HER3 therapy, HMBD-001.

Key Points: 
  • Hummingbird Bioscience, a clinical-stage biotechnology company, uses their proprietary and differentiated technologies to drug clinically-validated targets which have previously been elusive.
  • Leveraging Caris' extensive real-world clinico-genomic database to support clinical trial design, Hummingbird Bioscience will be better able to prospectively identify patients with molecular biomarkers that are potentially associated with response to HMBD-001.
  • "Caris' partnership with Hummingbird Bioscience aligns with our goal of leveraging molecular and clinical data to power and accelerate the development of precision therapies," said Brian Lamon , Ph.D., Chief Business Officer at Caris Life Sciences.
  • The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development.

Sapience Therapeutics Presents Data on the Immune Activating Function of ST101 at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Thursday, November 10, 2022

Validating these findings, subtherapeutic doses of ST101 significantly enhanced the anti-tumor activity of anti-PD1 antibodies in an orthotopic breast cancer tumor model.

Key Points: 
  • Validating these findings, subtherapeutic doses of ST101 significantly enhanced the anti-tumor activity of anti-PD1 antibodies in an orthotopic breast cancer tumor model.
  • Sapience believes that reprogramming MDSCs from the M2 to the M1 phenotype represents a potential strategy to enhance antitumor immunity.
  • Further details of the ST101 mechanism of action can be found on the company's website: ST101: Sapience Therapeutics, Inc.
  • Sapience Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing peptide therapeutics to address oncogenic and immune dysregulation that drive cancer.

Sapience Therapeutics Announces Publication Showcasing the Mechanism of Action and Anti-tumor Activity of ST101, a Novel and Selective Peptide Antagonist of C/EBPβ, in Molecular Cancer Therapeutics

Retrieved on: 
Monday, September 19, 2022

The full manuscript titled "Anti-cancer activity of ST101, a novel antagonist of CCAAT/enhancer binding protein ", can be found online here .

Key Points: 
  • The full manuscript titled "Anti-cancer activity of ST101, a novel antagonist of CCAAT/enhancer binding protein ", can be found online here .
  • ST101 exposure significantly decreases expression of C/EBP target genes including genes responsible for survival, transcription factors and cell cycle-related proteins.
  • "We are thrilled to publish the mechanism of action of ST101 and showcase the therapeutic promise of disrupting C/EBP-driven oncogenic activity.
  • Sapience Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing peptide therapeutics to address oncogenic and immunogenic dysregulation that drive cancer.

Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia

Retrieved on: 
Wednesday, August 17, 2022

The Companys innovatively-assembled and proprietary rose bengal is the lead member of a class of small molecules called halogenated xanthenes.

Key Points: 
  • The Companys innovatively-assembled and proprietary rose bengal is the lead member of a class of small molecules called halogenated xanthenes.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes (HXs).
  • Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements.
  • Risks, uncertainties, and assumptions include those discussed in the Companys filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:

Cipher Sports to Launch New Features with SharpSports Technology

Retrieved on: 
Wednesday, March 23, 2022

SharpSports is delighted to announce it has partnered with Cipher Sports Technology Group.

Key Points: 
  • SharpSports is delighted to announce it has partnered with Cipher Sports Technology Group.
  • The partnership will facilitate the integration of SharpSports' seemless bet tracking technology for the Dimers community, while at the same time also delivering analytics and personalized, relevant content back to users.
  • Dimers.com, the flagship product of Australia's Cipher Sports Technology Group, launched on August 1, 2020 and has rapidly made inroads into the burgeoning US market through its unique combination of betting content and user friendly technology and products.
  • "We're really excited to partner with SharpSports and integrate their bet tracking technology on to Dimers.com," said Cipher CEO, Adam Fiske.

Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies

Retrieved on: 
Monday, December 6, 2021

The trial intends to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and explore preliminary evidence of HMBD-001 activity in patients with advanced HER3-expressing solid malignancies, including NRG1 fusion-driven cancers.

Key Points: 
  • The trial intends to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and explore preliminary evidence of HMBD-001 activity in patients with advanced HER3-expressing solid malignancies, including NRG1 fusion-driven cancers.
  • "Dosing of the first patient in the clinical trial of HMBD-001, Hummingbird's most advanced program, marks the beginning of a potentially transformative approach to treating HER3-driven cancers," said Dr. Jerome Boyd-Kirkup, Chief Scientific Officer, Hummingbird Bioscience.
  • Hummingbird Bioscience is dedicated to discovering and developing important medicines for cancer and autoimmune disease with our unique Rational Antibody Discovery platform."
  • It currently has a portfolio of 21 new anti-cancer agents in preclinical development, Phase I or early Phase II clinical trials.

Blade Therapeutics Announces Publication of Preclinical Evidence Supporting Neuroprotective Effects of Proprietary Calpain Inhibitor in a Rare Inherited Neurodegenerative Disease

Retrieved on: 
Thursday, October 7, 2021

Also known as Machado Joseph Disease (MJD), SCA3/MJD is a rare, inherited (autosomal-dominant) neurological disorder.

Key Points: 
  • Also known as Machado Joseph Disease (MJD), SCA3/MJD is a rare, inherited (autosomal-dominant) neurological disorder.
  • We look forward to starting a planned phase 1 study evaluating our lead calpain inhibitor, BLD-2184, in the first half of 2022.
  • In the preclinical in vivo studies, a transgenic zebrafish model of SCA3/MJD was used to evaluate the prophylactic and therapeutic treatment effects of Blades proprietary small-molecule calpain inhibitor, BLD-2736.
  • Neuroscientists at Macquarie Medical School conducted the study, which was sponsored by Blade Therapeutics Pty Ltd, a wholly owned subsidiary of Blade Therapeutics, Inc.

Study Shows Masks Reduce Spread Of Virus In Classrooms

Retrieved on: 
Saturday, September 4, 2021

Now, with the new school year upon us, the CDC has provided guidelines including mask-wearing inside at school.

Key Points: 
  • Now, with the new school year upon us, the CDC has provided guidelines including mask-wearing inside at school.
  • Dr. Arthur Kreitenberg, Chief Innovation & Technology Officer and Co-Founder of Dimer said: "We advocate for objective and informed decision making and this demonstrative study affirms that mask-wearing reduces the spread of infectious germs like COVID-19.
  • We hope that schools and parents will take a look at the demonstration we conducted and be more informed."
  • The particles in thesimulation are 10x larger than a virus.

Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch

Retrieved on: 
Wednesday, September 1, 2021

Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs.

Key Points: 
  • Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs.
  • We are excited to expand our CaspaCIDe agreement with MD Anderson to include a broader set of programs to benefit cancer patients, said Rick Fair, President and CEO of Bellicum Pharmaceuticals.
  • Bellicum and MD Anderson have agreed on the first two programs for development concurrent with the execution of the agreement.
  • CaspaCIDe (inducible caspase-9, or iC9) is Bellicums chemical induction of dimerization (CID) safety switch technology designated to eliminate cells in the event of toxicity.

Dimer Lands Strategic Partnership With Honeywell Bringing Its "GermFalcon" Product-Line To Airline Recovery

Retrieved on: 
Wednesday, June 10, 2020

The arrangement brings Dimer's 6-year development of GermFalcon, now branded as the Honeywell UV Cabin System , to global aviation.

Key Points: 
  • The arrangement brings Dimer's 6-year development of GermFalcon, now branded as the Honeywell UV Cabin System , to global aviation.
  • This strategic partnership will separately enable Dimer to further commercialize and deploy its germicidal UV technology platform known as UVHammer for healthcare .
  • This breakthrough application of germicidal UV is expected to benefit public transportation, education, hospitality, buildings, theaters and arenas, and small businesses alike.
  • Dimer is an innovator in germicidal UV light technologies to reduce pathogens in healthcare, transportation and shared spaces.